HIV Drugs Market Competitive Research And Precise Outlook 2023 To 2030

1
Contrive Datum InsightsGlobal Research And
Consulting
A complete solution to explore all the potential
aspect to drive the growth of the business
industries.
HIV Drugs Market
2
About Us
Contrive Datum Insights (CDI) is a market
intelligence company providing global business
information reports and services. Our exclusive
blend of quantitative forecasting and trends
analysis provides forward-looking insight for
thousands of decision makers. CDIs experienced
team of Analysts, Researchers, and Consultants
uses proprietary data sources and various tools
and techniques to gather, and analyse
information. Our business offerings represent the
latest and the most reliable information
indispensable for businesses to sustain a
competitive edge. Each CDI syndicated research
report covers a different sector such as
chemicals, materials, metals mining,
pharmaceuticals, energy, automotive, food and
beverages, semiconductors, med-devices, consumer
goods and information technology. These reports
provide in-depth analysis and deep segmentation
to possible micro levels. With wider scope and
stratified research methodology, our syndicated
reports strive to serve the overall research
requirement of clients.
3
Services O?ered

• Market Intelligence Market Opportunity
  Assessment
• Market Size Segmentation
• Market Entry Strategy
• Competitor Benchmarking
• Pricing Intelligence
• Customer Intelligence
• Sourcing Intelligence
• New-Generation Products Technologies
• Distribution Sales Channel Assessment

4
Clientele
Some of the global leading clients that we have
served
5
Clientele
Some of the global leading clients that we have
served
6
Market Overview
At a CAGR of 3.8 between 2020 and 2027, the
global HIV drugs market is projected to grow from
its 2019 valuation of USD 30.89 billion to USD
34.54 billion by 2022 and USD 46.55 billion by
2030.One of the most serious and long-lasting
diseases is AIDS, caused by the human
immunodeficiency virus. Infected blood, sperm,
breast milk, or other bodily fluids can spread
the virus that causes AIDS. The World Health
Organization (WHO) estimates that by 2020, 37.1
million people around the world would be living
with HIV infection. An estimated 34,800 new cases
of HIV were diagnosed in the United States year
2019. The number of new HIV infections has
dropped by 8, from 37,800 in 2015 to 34,800 in
2019, following a period of stability. A total of
36,801 people in the United States and six of its
dependent territories were newly diagnosed with
HIV in 2019, a decrease of 9 from 2015. The
spread of HIV testing is not uniform from state
to state or area to region.Recent years have seen
consistent growth in the global HIV medications
market due to rising rates of HIV/AIDS diagnosis
and treatment advancements. Antiretroviral
therapy (ART) has helped to extend the lives of
millions of individuals living

7
By Region
Markets for HIV medications around the world have
been broken down by geography to look at trends
in places including North America, Latin America,
the Middle East, Asia-Pacific, Africa, Europe,
and India. In the near future, the HIV Drugs
market is expected to be led by the global
region. The worldwide industry is divided into
four sections based on geography North America,
Europe, Asia-Pacific, and RoW. By 2020, the North
American market is projected to be worth USD
20.27 billion, making it a key region in the
forecast. The spread of HIV in the United States
is partly attributable to the region's impact.
About 1.2 million people were living with HIV as
of the end of 2018, according to a report by the
CDC in 2021. With such a large pool of potential
buyers, the price of HIV medication is sure to
rise. The education and awareness of the local
populace also contribute to the development of
the area. The presence of major players providing
novel HIV medications for the treatment of HIV
infection is also expected to boost the expansion
of the market.Due to rising rates of HIV
infection and the concentration of HIV medicine
manufacturers in Europe, that area is projected
to become the second largest market throughout
the projection period. Furthermore, expanding
strategic alliances among European enterprises
will increase medicine supply, hence bolstering
market development in Europe. An illustration of
this is the July 2020 partnership between
Theratechnologies Europe Limited, a European
subsidiary of Theratechnologies Inc., and Loxxess
for the distribution of the antiviral medication
Trogarzo across
8
The Global HIV Drugs Market has been segmented
into

• By Type
• Multi-Class Combination Products
• Nucleoside Reverse Transcriptase Inhibitors
• Non-Nucleoside Reverse Transcriptase Inhibitors
• Protease Inhibitors
• Fusion Inhibitors
• Entry Inhibitors - CCR5 Co-Receptor Antagonist
• HIV Integrase Strand Transfer Inhibitor

• By Application
• Hospital Pharmacies
• Retail Pharmacies
• Online Pharmacies

9
The Global HIV Drugs Market has been segmented
into

• By Region
• Europe
• Germany
• France
• Italy
• Spain
• UK
• Nordic Countries
• Denmark
• Finland
• Iceland
• Sweden
• Norway
• Benelux Union
• Belgium
• The Netherlands
• Luxembourg
• Rest of Europe

• By Region
• North America
• US
• Canada
• Mexico
• Rest of North America
• The Middle East Africa
• Saudi Arabia
• UAE
• Egypt
• South Africa
• Rest of the Middle East Africa
• Latin America
• Brazil
• Argentina
• Rest of Latin America

• By Region
• Asia-Pacific
• Japan
• China
• India
• Australia
• South Korea
• Southeast Asia
• Indonesia
• Thailand
• Malaysia
• Singapore
• Rest of Southeast Asia
• Rest of Asia-Pacific

10
Strategic Development
In January 2021, the U.S. Food and medication
Administration (FDA) gave ViiV Healthcare
approval to sell Cabenuva, the first and only
full long-lasting regimen combo medication for
HIV therapy.U.S. Food and Drug Administration
(FDA) approval for the combination medications
PIFELTRO and DELSTRIGO was granted to Merck Sharp
Dohme Corp., a subsidiary of Merck Co., Inc.,
in September 2019. HIV-1 infected adults may
benefit from these medications. Efavirenz
tablets were first made available in the United
States by Mylan Inc. in February 2018. The first
available alternative to Sustiva is the pill form
of efavirenz. Treatment of HIV-1 infection, both
in adults and children, requires the use of many
antiretroviral drugs. The FDA granted approval
for Juluca in the United States to ViiV
Healthcare in November 2017. The viral infection
can be suppressed with just one dosage of Juluca,
an antiretroviral therapy (ART) regimen.According
to a press release from Unitaid and Clinton
Health Access Initiative Inc
11
Market Players

• Merck Dohme Corp. (Kenilworth, France)
• Gilead Science, Inc. (Foster city, USA)
• Janssen Pharmaceutical Inc. (Johnson and Johnson,
  Belgium)
• ViiV Healthcare (Research Triangle Park, U.S)
• Bristol-Myers Squibb Company (New York city, U.S)
• Mylan Pharmaceuticals (Canonsburg USA)
• Genentech (South San Francisco, USA)
• GlaxoSmithKline plc. (Brentford, U.K)

12
Customer Experiences
13

• By associating with Contrive Datum Insights (CDI)
  , customer can enjoy following benefits
• One-Stop-Destination for all research needs
  (Syndicate and Custom Reports)
• Reduced Budget and Faster Turnaround Time
• Focused Research Team - Contrive Datum Insights
  (CDI) can arrange a dedicated team of 2-3
  resources with 1 Research Manager , who will look
  after any ad-hoc needs of the client
• Dedicated Account Manager
• 24/7 availability for any custom needs of the
  client
• Flexible Partnering Model to accommodate clients
  research needs
• Access to Data-Cuts related to required Market
  for global region
• ? Industry Update on Weekly/Bi-Weekly/Monthly
  basis
• ? Market Trend Analysis on Monthly/Quarterly basis

Benefits of Association
14
Thank You!
To know more about us, please visit our website
www.contrivedatuminsights.com For sales queries
or new topics email us on anna_at_contrivedatuminsig
hts.com